Paediatrics Search
Paediatrics Paediatrics
constipation%20in%20children
CONSTIPATION IN CHILDREN

Constipation is a delay or difficulty in bowel movement persisting for ≥2 weeks.
It is a common digestive problem, not a disease, and usually not serious caused by changes in diet and early toilet training.
Constipation in children generally first happens in the toddler stage, between ages 2 and 4 years, with studies showing variation in gender-specific prevalence.
Functional constipation is  the one that cannot be explained by any anatomical, physiological, radiological or histological abnormalities.
Organic constipation is with identifiable physiological or organic cause.
Chronic constipation is the constipation that lasts for >8 weeks.

Drug Information

Dosage: Chronic constipation Starting dose (for 3 days): Adult & childn >15 yr 15-45 mL. Maintenance: 15-30 mL,

Agiolax
plantago ovata husks + plantago seeds + sennosides

Indication: Traditionally used for constipation.

Indication: Relief of constipation & helps in stool softening. Hepatic encephalopathy.

Indication: Constipation.

Indication: Constipation. Prep of diagnostic procedures, in pre- & post-op treatment & in conditions which require...

Indication: Relief of constipation eg, constipation in pregnancy & maintenance of regularity. Bowel function managemen...

Indication: Relief of occasional constipation.

Indication: Constipation, hepatic encephalopathy.

Indication: Constipation & portal systemic encephalopathy.

PyloBalance
lactobacillus reuteri

Indication: Health supplement for H pylori control.

1  /  2
1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Oseltamivir cuts recovery time for flu in real world
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Personalizing treatment for chronic angina with concomitant diseases
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Obeticholic acid heralds a new era for NASH
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Lancet Commission: Mandatory validation, specific standards needed to improve accuracy of BP devices
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).